• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Randy Osborne

Randy Osborne

Articles

ARTICLES

Amgen, Immunex Merger Finished, Prices At $10.3B

July 17, 2002
By Randy Osborne

Corgentech Series C Raises $50M For Bypass Research

July 17, 2002
By Randy Osborne
With a product in one Phase III trial and about to start another in peripheral bypass graft surgery, Corgentech Inc. took an infusion of $50 million in Series C financing that gives it enough cash to last "through the first or second quarter of 2004," said Richard Powers, vice president and chief financial officer. (BioWorld Today)
Read More

Pfizer To Buy Pharmacia In $60B Stock-Swap Deal

July 16, 2002
By Randy Osborne
Just when the market slowdown and summer's dog days had cast a torpor over the land, Pfizer Inc. sent a blast of cooling news across the pharmaceutical landscape, disclosing that it signed an agreement to buy Pharmacia Corp. in a $60 billion stock swap. (BioWorld Today)
Read More

Safer, Easier AIDS Treatments 'Name Of The Game' In Barcelona

July 15, 2002
By Randy Osborne
Although less often in the headlines during recent years, quietly murderous HIV has gone about its dark business worldwide with terrible efficiency. AIDS has killed 20 million people since beginning that sinister march across the earth, and another 40 million are infected with the virus. (BioWorld Financial Watch)
Read More

AGY Therapeutics Series C: $31.3M For Three Programs

July 11, 2002
By Randy Osborne
AGY Therapeutics Inc. netted $31.3 million in a Series C financing for its work with small molecules against ischemic stroke and Alzheimer's disease, predicting it will have a product ready for the clinic "toward the second half of next year," said Karoly Nikolich, founder and CEO. (BioWorld Today)
Read More

MetaPhore's $30M Financing To Push Packaged Enzymes'

July 11, 2002
By Randy Osborne

QBI Buys Microarray Goods Plus Personnel From Incyte

July 9, 2002
By Randy Osborne
Quark Biotech Inc. paid an undisclosed sum for the microarray facilities and personnel of Incyte Genomics Inc., thereby beefing the former's profiling and chemical screening capabilities and completing another piece of the latter's restructuring.
Read More

Arius Lines Up Functional' Antibodies Against Cancer

July 9, 2002
By Randy Osborne

Food Labeling Debate Simmers; U.S. Rules Called 'Good Enough'

July 8, 2002
By Randy Osborne
During the 1960s, labels of any kind were abhorred by many for the way they so fixedly identified objects and people, limiting them to a static condition that idealistic New Agers whose cultural influence spread far in that era could hardly abide. (BioWorld Financial Watch)
Read More

Lively Field Of Enzyme Therapy Promises To Grow Even Hotter

July 1, 2002
By Randy Osborne
You don't need much, but you better have some or else. The subject is enzymes, replacement therapy for which has been in the forefront in June, with big player Genzyme General Corp. and partner BioMarin Pharmaceuticals Inc. making headlines (good news), as well as competitor Oxford GlycoSciences plc (bad news). (BioWorld Financial Watch)
Read More
View All Articles by Randy Osborne

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 28, 2025.
  • Boston Scientific Acurate Prime Aortic Valve System

    In TAVR setback, Boston Sci pulls plug on Acurate valves

    BioWorld MedTech
    Boston Scientific Corp. reported the latest setback in its transcatheter aortic valve replacement (TAVR) aspirations with the news that it is officially...
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe